Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,867 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01613482 | TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention(TSARINE) | terminated | Phase 3 | 13 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04251533 | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss(EPIK-B3) | terminated | Phase 3 | 137 | Novartis PharmaceuticalsINDUSTRY | 30 | Sep 10, 2026 |
| clinicaltrials |
| NCT05747794 | Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy(AIPAC-003) | terminated | Phase 2 / Phase 3 | 72 | Immutep S.A.S.INDUSTRY | 5 | Jul 30, 2026 | clinicaltrials |
| NCT03439046 | Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant(BioItaLEE) | terminated | Phase 3 | 287 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05207709 | Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype(HARMONIA) | terminated | Phase 3 | 61 | SOLTI Breast Cancer Research GroupOTHER | 3 | Jun 25, 2026 | clinicaltrials |
| NCT00520975 | Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU | terminated | Phase 3 | 96 | National Cancer Institute (NCI)NIH | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03199885 | Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer | terminated | Phase 3 | 190 | National Cancer Institute (NCI)NIH | 2 | May 29, 2026 | clinicaltrials |
| NCT02525211 | Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment | terminated | Phase 3 | 59 | Institut Paoli-CalmettesOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT00210236 | Surgical Breast Resection With or Without Axillary Lymph Node Excision in Treating Women With Breast Cancer(AXIL95) | terminated | Phase 3 | 625 | Institut BergoniéOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT03598712 | Local Compression Seroma DIminution Objective (CLODIS)(CLODIS) | terminated | Phase 3 | 60 | Centre Francois BaclesseOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT04478266 | Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer(AMEERA-5) | terminated | Phase 3 | 1,068 | SanofiINDUSTRY | 30 | Sep 11, 2025 | clinicaltrials |
| NCT04815083 | Fluorescence Imaging of Carcinoma During Breast Conserving Surgery | terminated | Phase 3 | 57 | SBI ALApharma Canada, Inc.INDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT04752332 | A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer(eMonarcHER) | terminated | Phase 3 | 111 | Eli Lilly and CompanyINDUSTRY | 20 | Jul 15, 2025 | clinicaltrials |
| NCT03936933 | Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer | terminated | Phase 3 | 6 | Eurofarma Laboratorios S.A.INDUSTRY | 1 | Feb 17, 2025 | clinicaltrials |
| NCT03498716 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer(IMpassion030) | terminated | Phase 3 | 2,199 | Hoffmann-La RocheINDUSTRY | 31 | Aug 21, 2024 | clinicaltrials |
| NCT04395339 | GM1 Prophylaxis for WBRT Related Cognitive Dysfunction(GLORY) | terminated | Phase 3 | 51 | Sun Yat-sen UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT05239663 | GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer | terminated | Phase 3 | 76 | Sun Yat-sen UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT05207514 | Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer | terminated | Phase 3 | 26 | Samyang Biopharmaceuticals CorporationINDUSTRY | 1 | May 17, 2024 | clinicaltrials |
| NCT05134194 | A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer | terminated | Phase 3 | 1 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT05065411 | Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer(VERU-024) | terminated | Phase 3 | 5 | Veru Inc.INDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04869943 | Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer(ARTEST) | terminated | Phase 3 | 52 | Veru Inc.INDUSTRY | 4 | Jan 26, 2024 | clinicaltrials |
| NCT03786094 | Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer(FORTRESS) | terminated | Phase 3 | 432 | Spexis AGINDUSTRY | 13 | Nov 1, 2023 | clinicaltrials |
| NCT04385433 | A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer(PRAVAPREV-01) | terminated | Phase 3 | 15 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 2 | Aug 24, 2023 | clinicaltrials |
| NCT03152929 | Paravertebral Block (PVC) Versus Pectoral Nerve Block (PEC) | terminated | Phase 3 | 89 | Corewell Health WestOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT04335006 | A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer. | terminated | Phase 3 | 80 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 6, 2023 | clinicaltrials |
| NCT00272987 | ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib | terminated | Phase 3 | 63 | Novartis PharmaceuticalsINDUSTRY | 2 | Apr 28, 2023 | clinicaltrials |
| NCT00004935 | Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2 | terminated | Phase 3 | 175 | Swiss Cancer InstituteOTHER | 2 | Apr 18, 2023 | clinicaltrials |
| NCT03354611 | Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging | terminated | Phase 2 / Phase 3 | 21 | Koning CorporationINDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT00543127 | Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole | terminated | Phase 3 | 870 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT01905592 | A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients(BRAVO) | terminated | Phase 3 | 216 | Tesaro, Inc.INDUSTRY | 14 | Nov 15, 2022 | clinicaltrials |
| NCT03674242 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2) | terminated | Phase 2 / Phase 3 | 27 | ERYtech PharmaINDUSTRY | 3 | Aug 1, 2022 | clinicaltrials |
| NCT02340221 | A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy(SANDPIPER) | terminated | Phase 3 | 631 | Hoffmann-La RocheINDUSTRY | 28 | Jul 12, 2022 | clinicaltrials |
| NCT01067144 | Stanford Accelerated Recovery Trial (START) | terminated | Phase 3 | 422 | Stanford UniversityOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT01077154 | Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) | terminated | Phase 3 | 4,509 | AmgenINDUSTRY | 39 | Sep 28, 2021 | clinicaltrials |
| NCT00508274 | Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China | terminated | Phase 3 | 52 | Novartis PharmaceuticalsINDUSTRY | 2 | Sep 21, 2021 | clinicaltrials |
| NCT03326674 | Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC(CONTESSA) | terminated | Phase 3 | 685 | Odonate Therapeutics, Inc.INDUSTRY | 19 | Jul 30, 2021 | clinicaltrials |
| NCT03905343 | Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC | terminated | Phase 3 | 25 | Swiss Cancer InstituteOTHER | 3 | Jun 16, 2021 | clinicaltrials |
| NCT00296010 | Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer(CASA) | terminated | Phase 3 | 77 | ETOP IBCSG Partners FoundationNETWORK | 9 | Feb 23, 2021 | clinicaltrials |
| NCT02730091 | A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease(VICTORIANE) | terminated | Phase 3 | 98 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02137837 | S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer | terminated | Phase 3 | 37 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 28, 2021 | clinicaltrials |
| NCT03055312 | Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer(SYSUCC-007) | terminated | Phase 3 | 36 | Sun Yat-sen UniversityOTHER | 1 | Jan 28, 2021 | clinicaltrials |
| NCT00448266 | Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD | terminated | Phase 2 / Phase 3 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT00625898 | BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab(BETH) | terminated | Phase 3 | 3,509 | NSABP Foundation IncNETWORK | 40 | Sep 10, 2020 | clinicaltrials |
| NCT03050398 | A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib | terminated | Phase 3 | 8 | Novartis PharmaceuticalsINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT02532400 | Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients(COMPETE) | terminated | Phase 3 | 21 | Ruijin HospitalOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT01902823 | Effect of Cancer Nurse Navigators on Patient Outcomes | terminated | Phase 2 / Phase 3 | 16 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT02054338 | A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer(VICTORIA) | terminated | Phase 3 | 1,004 | Pierre Fabre MedicamentINDUSTRY | 0 | Aug 28, 2019 | clinicaltrials |
Data updated 13 days agoSource updated Sep 17, 2026source: clinicaltrials